AAAyodeji A. Asuni

Ayodeji A. Asuni

*This is an algorithmically generated author record based on publicly available information.

Ayodeji A. Asuni has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Highly Sensitive Assays for detection of headache inducing neuropeptides, Pituitary adenylate cyclase-activating polypeptide (PACAP) and Calcitonin gene-related peptide (CGRP)

    by Ourania Tzara, Josefine Nielsen Søderberg, Justyna Bahl, Emelie Andersson, Dina Silke Malling Damlund, Ib Vestergaard-Klewe, Mikkel Nors Harndahl, Allan Jensen, Ayodeji A. Asuni

    Background: Migraine is one of the most disabling diseases that continues to pose a significant societal burden. Although there are now treatment options for people with migraine, it remains challenging to identify them as clinical features are diverse and complex, and there are no validated diagnostic or treatment prediction biomarkers. Identification is based on either diagnostic coding or the use of certain acute headache abortive treatments. However, socioeconomic disparities can contribute to under-diagnosis and under-treatment of migraine. Thus, efforts to find biomarkers to identify individuals with migraine and which variables could explain migraine-related chronification and disability are warranted. We aimed to investigate the levels of migraine inducing neuropeptides; calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in peripheral blood samples as potential biomarkers of migraine. Methods: We developed highly sensitive assays for CGRP and PACAP on the MSD S-PLEX assay platform and used them for bioanalysis of preclinical and clinical samples. Wildtype and neuropeptide challenged mice and rats were profiled using the developed assay. To follow-up, commercially obtained plasma samples from healthy controls and migraineurs were initially profiled. Subsequently, we profiled plasma samples from people with migraine (during and after a headache attack and healthy controls. Both MSD S-PLEX assays were transferred to Celerion where they were validated for analysis of clinical samples. Results: Using the highly sensitive PACAP assay, we were able to reliably measure circulating levels of endogenous and administrated PACAP38in mouse and rat plasma. Additionally, using the highly sensitive CGRP assay, we were able to reliably measure circulating levels of endogenous and administrated CGRP in mouse and rat plasma. Furthermore, in the initial human samples, circulating CGRP and PACAP levels were not significantly different in healthy controls compared to people with migraine patients. However, ≥50% people with migraine showed increased circulating CGRP and PACAP levels during their attack period compared to post attack. Overall, people with migraine showed a 3 – 396% increase in one or both neuropeptides during their attack period compared to post attack. Circulating plasma CGRP and PACAP levels in healthy control subjects were consistent with previously measured levels. Conclusion: Our highly sensitive PACAP and CGRP assays were successful in measuring circulating levels of endogenous PACAP38 and CGRP in mouse and rat plasma. Our highly sensitive PACAP and CGRP assays were qualified for measurement of human CGRP and PACAP in healthy control and migraine samples. Plasma CGRP and PACAP levels are elevated in migraineurs during an attack period, and the increased plasma neuropeptide levels during an attack may help the differentiation of migraineurs from non-Migraineurs, or amongst people with migraines to help identify the best treatment for each patient.

  • Amyloid-β targeting immunisation in aged non-human primate (Microcebus murinus)

    by Stéphanie G. Trouche, Allal Boutajangout, Ayodeji Asuni, Pascaline Fontés, Einar M. Sigurdsson, Jean-Michel Verdier, Nadine Mestre-Francés


  • Dual strategy for reduced signal‐suppression effects in matrix‐assisted laser desorption/ionization mass spectrometry imaging

    by Joakim Bastrup, Svend Birkelund, Ayodeji A. Asuni, Christiane Volbracht, Allan Stensballe

    Rationale: The molecular complexity of tissue features several signal‐suppression effects which reduce the ionization of analytes significantly and thereby weakens the quality of matrix‐assisted laser desorption/ionization (MALDI) mass spectrometry (MS) imaging (MALDI imaging). We report a novel approach in MALDI imaging by reducing signal‐suppression effects for the analysis of beta‐amyloid (Aβ) plaques, one pathological hallmark of Alzheimer's disease (AD). Methods: We analyzed Aβ proteoforms from postmortem AD brains and brains from transgenic mice (APPPS1‐21) overexpressing familial AD mutations by combining two techniques: (1) laser capture microdissection (LCM) to accumulate Aβ plaques and (2) phosphoric acid (PA) as additive to the super‐2,5‐dihydroxybenzoic acid matrix. Results: LCM and MALDI‐MS enabled tandem mass spectrometric fragmentation of stained Aβ plaques. PA improved the signal‐to‐noise (S/N) ratio, especially of the Aβ1‐42 peptide, by three‐fold compared with the standard matrix additive trifluoroacetic acid. The beneficial effect of the PA matrix additive in MALDI imaging was particularly important for AD brain tissue. We identified several significant differences in Aβ plaque composition from AD compared with APPPS1‐21, underlining the value of reducing signal‐suppressing effects in MALDI imaging. Conclusions: We present a novel strategy for overcoming signal‐suppression effects in MALDI imaging of Aβ proteoforms.


  • Change in tau phosphorylation associated with neurodegeneration in the ME7 model of prion disease

    by Ayodeji A. Asuni, V. Hugh Perry, Vincent O'Connor

    Hyperphosphorylation of the microtubule-associated protein tau is a significant determinant in AD (Alzheimer's disease), where it is associated with disrupted axonal transport and probably causes synaptic dysfunction. Although less well studied, hyperphosphorylation has been observed in prion disease. We have investigated the expression of hyperphosphorylated tau in the hippocampus of mice infected with the ME7 prion agent. In ME7-infected animals, there is a selective loss of CA1 synapse, first discernable at 13 weeks of disease. There is a potential that dysfunctional axonal transport contributes to this synaptopathy. Thus investigating hyperphosphorylated tau that is dysfunctional in AD could illuminate whether and how they are significant in prion disease. We observed no differences in the levels of phosphorylated tau (using MC1, PHF-1 and CP13 antibodies) in detergent-soluble and detergent-insoluble fractions extracted from ME7- and NBH- (normal brain homogenate) treated animals across disease. In contrast, we observed an increase in phospho-tau staining for several epitopes using immunohistochemistry in ME7-infected hippocampal sections. Although the changes were not of the magnitude seen in AD tissue, clear differences for several phospho-tau species were seen in the CA1 and CA3 of ME7-treated animals (pSer199−202>pSer214>PHF-1 antibody). Temporally, these changes were restricted to animals at 20 weeks and none of the disease-related staining was associated with the axons or dendrites that hold CA1 synapses. These findings suggest that phosphorylation of tau at the epitopes examined does not underpin the early synaptic dysfunction. These data suggest that the changes in tau phosphorylation recorded here and observed by others relate to end-stage prion pathology when early dysfunctions have progressed to overt neuronal loss.


  • Alpha-synuclein deficiency in the C57BL/6JOlaHsd strain does not modify disease progression in the ME7-model of prion disease

    by A.A. Asuni, K. Hilton, Z. Siskova, K. Lunnon, R. Reynolds, V.H. Perry, V. O'COnnor